Shuichi Ohtomo Selected Research

Phosphate Transport Proteins (Phosphate Transporter)

1/2022	EOS789, pan-phosphate transporter inhibitor, ameliorates the progression of kidney injury in anti-GBM-induced glomerulonephritis rats.
1/2021	Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease.
1/2020	EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder.
1/2020	Significant Species Differences in Intestinal Phosphate Absorption between Dogs, Rats, and Monkeys.
6/2018	Effect of Npt2b deletion on intestinal and renal inorganic phosphate (Pi) handling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shuichi Ohtomo Research Topics

Disease

5	Chronic Renal Insufficiency 01/2022 - 11/2011
5	Hyperphosphatemia 01/2022 - 11/2011
3	Hypertension (High Blood Pressure) 01/2010 - 04/2008
3	Obesity 01/2010 - 04/2008
3	Diabetic Nephropathies (Diabetic Nephropathy) 09/2009 - 09/2008
2	Kidney Diseases (Kidney Disease) 01/2022 - 10/2008
2	Hyperglycemia 01/2010 - 09/2008
2	Proteinuria 09/2009 - 04/2008
1	Glomerulonephritis 01/2022
1	Nephritis 01/2022
1	Bone Diseases (Bone Disease) 01/2022
1	Chronic Kidney Disease-Mineral and Bone Disorder (Renal Rickets) 01/2020
1	Gout 04/2016
1	Hyperuricemia 04/2016
1	Renal Insufficiency (Renal Failure) 11/2011
1	Hyperinsulinism (Hyperinsulinemia) 01/2010
1	Body Weight (Weight, Body) 01/2010
1	Inflammation (Inflammations) 01/2010
1	Hyperlipidemias (Hyperlipidemia) 01/2010
1	Hyperphagia (Overeating) 09/2009
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2009
1	Albuminuria 12/2008
1	Type 2 Diabetes Mellitus (MODY) 04/2008
1	Hypoxia (Hypoxemia) 04/2008

Drug/Important Bio-Agent (IBA)

5	Phosphate Transport Proteins (Phosphate Transporter)IBA 01/2022 - 06/2018
4	Phosphates (Orthophosphate)IBA 01/2022 - 11/2011
3	SodiumIBA 01/2022 - 01/2020
2	CreatinineIBA 01/2022 - 11/2011
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2022
2	MineralsIBA 01/2022 - 01/2020
2	Adenine FDA LinkGeneric 01/2020 - 11/2011
2	Angiotensin II Type 1 Receptor BlockersIBA 09/2009 - 12/2008
1	AntibodiesIBA 01/2022
1	antiglomerular basement membrane antibodyIBA 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Fibroblast Growth Factor-23IBA 01/2020
1	Parathyroid Hormone (Parathormone)IBA 01/2020
1	UR-1102IBA 04/2016
1	Uric Acid (Urate)IBA 04/2016
1	AdiponectinIBA 01/2010
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2010
1	CarbohydratesIBA 01/2010
1	Leptin ReceptorsIBA 09/2009
1	Biomarkers (Surrogate Marker)IBA 09/2009
1	Valsartan (Vals)FDA Link 09/2009
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 12/2008
1	olmesartanIBA 12/2008
1	Antihypertensive Agents (Antihypertensives)IBA 12/2008
1	Receptor for Advanced Glycation End ProductsIBA 12/2008
1	Angiotensin Receptor AntagonistsIBA 12/2008
1	R 147176IBA 10/2008
1	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 09/2008
1	Messenger RNA (mRNA)IBA 09/2008
1	Matrix Metalloproteinases (MMPs)IBA 09/2008
1	Fibrinolysin FDA Link 09/2008
1	Glucose (Dextrose)FDA LinkGeneric 09/2008
1	CobaltIBA 04/2008

Therapy/Procedure

1	Therapeutics 04/2016
1	Renal Dialysis (Hemodialysis) 11/2011
1	Glycemic Control 01/2010
1	Fat-Restricted Diet (Diet, Fat Restricted) 01/2010